Teneobio

Teneobio was a privately held, clinical-stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb), for the treatment of cancer, autoimmunity, and infectious diseases. Its TeneoSeek discovery platform combined genetically engineered animals (UniRat, OmniFlic), next-generation sequencing, bioinformatics, and high-throughput vector assembly. Teneobio was surfaced as a portfolio company of Lightspeed Venture Partners and added to the API Evangelist network as an enrichment lead. Amgen acquired Teneobio in October 2021 for $900 million upfront plus up to $1.6 billion in contingent milestone payments; the company no longer operates independently and publishes no live developer surface. This is a life-sciences / therapeutics company with no public API, developer portal, or machine-readable API artifacts.

Teneobio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Antibody Therapeutics, and Life Sciences.

🌐 Visit website 📡 Source on GitHub
2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyPharmaceuticalsAntibody TherapeuticsLife SciencesDrug DiscoveryOncology

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 2.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 0.0 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/teneobio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

apis.yml Raw ↑ 
aid: teneobio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/teneobio.png
name: Teneobio
description: Teneobio was a privately held, clinical-stage biotechnology company developing a new class of biologics, Human
  Heavy-Chain Antibodies (UniAb), for the treatment of cancer, autoimmunity, and infectious diseases. Its TeneoSeek discovery
  platform combined genetically engineered animals (UniRat, OmniFlic), next-generation sequencing, bioinformatics, and high-throughput
  vector assembly. Teneobio was surfaced as a portfolio company of Lightspeed Venture Partners and added to the API Evangelist
  network as an enrichment lead. Amgen acquired Teneobio in October 2021 for $900 million upfront plus up to $1.6 billion
  in contingent milestone payments; the company no longer operates independently and publishes no live developer surface.
  This is a life-sciences / therapeutics company with no public API, developer portal, or machine-readable API artifacts.
url: https://raw.githubusercontent.com/api-evangelist/teneobio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- lightspeed-venture-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: amgen
x-acquired-date: '2021-10-19'
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Antibody Therapeutics
- Life Sciences
- Drug Discovery
- Oncology
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: nochange
  artifacts_added: 0
  pass: local-v1